UniQure Shares Outstanding 2013-2022 | QURE

UniQure shares outstanding from 2013 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
UniQure Annual Shares Outstanding
(Millions of Shares)
2021 47
2020 44
2019 40
2018 36
2017 27
2016 25
2015 22
2014 17
2013 11
2012 9
UniQure Quarterly Shares Outstanding
(Millions of Shares)
2022-03-31 47
2021-12-31 47
2021-09-30 46
2021-06-30 47
2021-03-31 45
2020-12-31 44
2020-09-30 44
2020-06-30 44
2020-03-31 44
2019-12-31 40
2019-09-30 41
2019-06-30 38
2019-03-31 38
2018-12-31 36
2018-09-30 37
2018-06-30 36
2018-03-31 32
2017-12-31 27
2017-09-30 26
2017-06-30 26
2017-03-31 25
2016-12-31 25
2016-09-30 25
2016-06-30 25
2016-03-31 25
2015-12-31 22
2015-09-30 21
2015-06-30 22
2015-03-31 18
2014-12-31 18
2014-09-30 18
2014-06-30 18
2014-03-31 15
2013-12-31
2013-09-30
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.640B $0.524B
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00